НовостиBenzingaCanaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 Benzinga 2026.11.09 18:02 (GMT+0) Открыть на Benzinga Другие новости